Glaukos Balance Sheet Health
Financial Health criteria checks 3/6
Glaukos tiene unos fondos propios totales de $477.7M y una deuda total de $282.4M, lo que sitúa su ratio deuda/fondos propios en 59.1%. Sus activos y pasivos totales son $948.6M y $471.0M respectivamente.
Key information
61.2%
Debt to equity ratio
US$282.77m
Debt
| Interest coverage ratio | n/a |
| Cash | US$295.43m |
| Equity | US$461.77m |
| Total liabilities | US$478.65m |
| Total assets | US$940.41m |
Recent financial health updates
Is Glaukos (NYSE:GKOS) A Risky Investment?
Jan 21
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Oct 05Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Feb 19Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Oct 16Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Recent updates
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price
Feb 21Is Glaukos (NYSE:GKOS) A Risky Investment?
Jan 21Glaukos: Remains A Hold Due To High Valuation And Negative Profitability
Jan 09Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors
Dec 20Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching
Nov 03Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Oct 05Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support
Sep 01Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Glaukos: Revising To Buy On These 3 Catalytic Factors
Jun 16Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)
Apr 19Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?
Feb 19Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through
Feb 14Glaukos sees positive data from mid-stage trial of dry eye treatment
Jan 10Glaukos: Show Me The Money
Nov 10Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Oct 16Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80
Aug 24Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision
Aug 04Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside
Jul 12Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Jun 28Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?
Mar 14Is Glaukos (NYSE:GKOS) Using Debt Sensibly?
Nov 29Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Aug 15Financial Position Analysis
Pasivos a corto plazo: GKOSLos activos a corto plazo ($399.5M) de la empresa superan a sus pasivos a corto plazo ($67.1M).
Pasivo a largo plazo: Los activos a corto plazo de GKOS ($399.5M) no cubren sus pasivos a largo plazo ($403.8M).
Debt to Equity History and Analysis
Nivel de deuda: GKOS tiene más efectivo que su deuda total.
Reducción de la deuda: GKOSha pasado de 0% a 59.1% en los últimos 5 años.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: GKOS tiene suficiente cash runway para más de 3 años basándose en su free cash flow actual.
Pronóstico de cash runway: Datos insuficientes para determinar si GKOS tiene suficiente margen de liquidez en caso de que su flujo de caja libre siga creciendo o disminuyendo en función de las tasas históricas.